A gentler drug pair beat intensive chemo on one measure in fit leukaemia patients

For decades, the fittest adults diagnosed with acute myeloid leukaemia (AML) have been offered intensive induction chemotherapy — a treatment that can cure but comes with frequently severe side effects and heavy hospital use [s1]. A trial published in the New England Journal of Medicine on 2 September asks whether a gentler two-drug combination, already standard for patients too frail for chemotherapy, might be better even for those who could tolerate the intensive route [s1].

The question, and why it is a good one

The combination is azacitidine plus venetoclax. For patients ineligible for induction chemotherapy, that pairing is already the standard treatment, owing to its efficacy and side-effect profile [s1]. What had not been tested head-to-head is whether it also holds up in fit, induction-eligible patients — the group that has always been steered toward the harder regimen. The PARADIGM trial put that assumption to a randomised test [s1].

What the trial did

PARADIGM was a multicenter, phase 2 trial that randomly assigned, 1:1, previously untreated adults with AML who were eligible for induction chemotherapy to receive either azacitidine plus venetoclax or induction chemotherapy [s1]. It deliberately excluded several biologically favourable subgroups — patients with core binding factor fusions, FLT3 mutations, or NPM1 mutations (the last unless the patient was 60 or older) — focusing the comparison on higher-risk disease [s1]. The primary end point was event-free survival [s1].

A total of 172 patients underwent randomisation, 86 to each group, with a median age of 64; 72% had adverse-risk disease by the European LeukemiaNet 2022 classification [s1]. That last figure matters: this was a high-risk population, not a favourable one. The European LeukemiaNet system sorts newly diagnosed AML into favourable, intermediate and adverse categories on genetic grounds, and adverse-risk disease is the group that tends to do worst with standard chemotherapy — so a trial weighted 72% toward it was testing the drug combination where the need is greatest and the bar, in some respects, lowest.

The result

At a median follow-up of 21.9 months, median event-free survival was 14.5 months (95% confidence interval 10.4 to 24.4) in the azacitidine–venetoclax group, compared with 6.2 months (95% CI 4.1 to 10.1) in the induction-chemotherapy group [s1]. That corresponds to a hazard ratio for an event or death of 0.57 (95% CI 0.39 to 0.84; P = 0.002) — a statistically significant advantage for the drug combination on this end point [s1].

The safety comparison ran the same direction. Grade 3 or higher infection occurred in 28% of patients (95% CI 19 to 39) receiving azacitidine–venetoclax versus 41% (95% CI 30 to 52) with induction chemotherapy, and grade 3 or higher haemorrhage in 2% (95% CI 0.3 to 8) versus 12% (95% CI 6 to 20) [s1]. Fewer serious infections and bleeds is exactly what a lower-intensity regimen is supposed to deliver.

The caveats that keep this from being a verdict

Three limits deserve to sit next to the headline. First, this was a phase 2 trial of 172 patients — sized to detect a signal, not to settle the question. Second, the primary end point was event-free survival, not overall survival; living longer without an event is meaningful, but it is not the same as living longer, and the abstract's reported end point is event-free survival, not a mortality difference [s1]. Third, the trial excluded several favourable genetic subgroups, so the result speaks to higher-risk AML rather than to every fit patient.

The New England Journal of Medicine published the trial alongside an editorial framing the broader question of hypomethylating agents plus venetoclax versus intensive chemotherapy in AML [s2] — a sign that the field regards this as an open, consequential comparison rather than a closed case.

Why it matters

If a lower-intensity regimen can match or beat intensive chemotherapy on the outcomes that matter, with fewer serious complications, that would reshape how newly diagnosed AML is treated even in patients well enough for the hard option. PARADIGM is a strong signal in that direction on event-free survival; it is not yet the overall-survival, phase 3 evidence that would make it standard. The trial was funded by AbbVie and others (PARADIGM; ClinicalTrials.gov number NCT04801797) [s1].

This article summarises a single phase 2 trial and does not offer medical advice.

Sources

• Azacitidine–Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia, New England Journal of Medicine, 2 September 2026
• Hypomethylating Agents plus Venetoclax as Compared with Intensive Chemotherapy in Patients with AML (Editorial), New England Journal of Medicine, 1 September 2026